Afamelanotide is an α-melanocyte-stimulating hormone (α-MSH) agonist with proven efficacy in photodermatoses such as erythropoietic protoporphyria (EPP). This peptide drug, repeatedly administered over prolonged time, may induce anti-drug antibodies (ADA). Here, we describe a new ELISA method developed to monitor the occurrence of ADA against afamelanotide as well as against α-MSH. Covalent binding instead of absorption of antigen onto the microtitre wells prevented antigen leakage and enabled extensive washings followed by lower background. The cut-off between antibody-negative and -positive sera was determined. Inhibition of the antigen-antibody reaction by excess soluble antigen tested for specificity. The sensitivity of the ELISA was 608 and 1,390 ng/ml of specific ADA against afamelanotide and α-MSH, respectively. This ELISA method enabled us to investigate the occurrence of ADA during long-term administration of afamelanotide. No immunoreactivity was found in 23 of the 26 EPP patients exposed to the drug for up to 6 years. Pre-existing immunoreactivity against afamelanotide as well as α-MSH was found in 3 patients, whose titres did not change during afamelanotide administration. Conclusion: The new ELISA is suitable to determine ADA against afamelanotide and α-MSH. Afamelanotide did not elicit ADA during long-term administration in patients with EPP. © 2014 S. Karger AG, Basel

1.
Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE: Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-alpha-MSH. Br J Dermatol 2011;164:407-414.
2.
Harms J, Lautenschlager S, Minder CE, Minder EI: An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009;360:306-307.
3.
Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME: 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980;77:5754-5758.
4.
Dorr RT, Dawson BV, al-Obeidi F, Hadley ME, Levine N, Hruby VJ: Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH. Invest New Drugs 1988;6:251-258.
5.
Sela M: Antigenicity: some molecular aspects. Science 1969;166:1365-1374.
6.
Mariani M, Bracci L, Presentini R, Nucci D, Neri P, Antoni G: Immunogenicity of a free synthetic peptide: carrier-conjugation enhances antibody affinity for the native protein. Mol Immunol 1987;24:297-303.
7.
Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475.
8.
Bhardwaj R, Blanchard J: In vitro characterization and in vivo release profile of a poly (D,L-lactide-co-glycolide)-based implant delivery system for the alpha-MSH analog, melanotan-I. Int J Pharm 1998;170:109-117.
9.
Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA: Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16.
10.
Dwyer T, Blizzard L, Ashbolt R, Plumb J, Berwick M, Stankovich JM: Cutaneous melanin density of Caucasians measured by spectrophotometry and risk of malignant melanoma, basal cell carcinoma, and squamous cell carcinoma of the skin. Am J Epidemiol 2002;155:614-621.
11.
Jensen SP, Rasmussen SE, Jakobson MH: Photochemical coupling of peptides to polystyrene microwell plates; in Epton R (ed): Innovation and Perspectives in Solid Phase Synthesis and Combinatorial Libraries. Proc 4th Int Symp on Solid Phase Synthesis. Paris, Intercept, 1996.
12.
Harlow E, Lane D: Antibodies. A Laboratory Manual. New York, Cold Spring Harbor Laboratory, 1988.
13.
Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E: Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008;48:1267-1281.
14.
Baker MP, Reynolds HM, Lumicisi B, Bryson CJ: Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010;1:314-322.
15.
Geng D, Shankar G, Schantz A, Rajadhyaksha M, Davis H, Wagner C: Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal 2005;39:364-375.
16.
Fetissov SO, Harro J, Jaanisk M, Jarv A, Podar I, Allik J, Nilsson I, Sakthivel P, Lefvert AK, Hokfelt T: Autoantibodies against neuropeptides are associated with psychological traits in eating disorders. Proc Natl Acad Sci USA 2005;102:14865-14870.
17.
Philip R, Carrington L, Chan M: US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics. Bioanalysis 2011;3:383-389.
18.
Aebischer I, Stämpfli MR, Zürcher A, Miescher S, Urwyler A, Frey B, Luger T, White RR, Stadler BM: Neuropeptides are potent modulators of human in vitro immunoglobulin E synthesis. Eur J Immunol 1994;24:1908-1913.
19.
Rheins LA, Cotleur AL, Kleier RS, Hoppenjans WB, Saunder DN, Nordlund JJ: Alpha-melanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice. J Invest Dermatol 1989;93:511-517.
20.
Lipton JM, Macaluso A, Hiltz ME, Catania A: Central administration of the peptide alpha-MSH inhibits inflammation in the skin. Peptides 1991;12:795-798.
21.
Grabbe S, Bhardwaj RS, Mahnke K, Simon MM, Schwarz T, Luger TA: Alpha-melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J Immunol 1996;156:473-478.
22.
Raap U, Brzoska T, Sohl S, Path G, Emmel J, Herz U, Braun A, Luger T, Renz H: Alpha-melanocyte-stimulating hormone inhibits allergic airway inflammation. J Immunol 2003;171:353-359.
23.
Cooper A, Robinson SJ, Pickard C, Jackson CL, Friedmann PS, Healy E: Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol 2005;175:4806-4813.
24.
Jahn EM, Schneider CK: How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. N Biotechnol 2009;25:280-286.
25.
Fetissov SO, Hallman J, Oreland L, Af KB, Grenback E, Hulting AL, Hokfelt T: Autoantibodies against alpha-MSH, ACTH, and LHRH in anorexia and bulimia nervosa patients. Proc Natl Acad Sci USA 2002;99:17155-17160.
26.
Sinno MH, do Rego JC, Coeffier M, Bole-Feysot C, Ducrotte P, Gilbert D, Tron F, Costentin J, Hokfelt T, Dechelotte P, Fetissov SO: Regulation of feeding and anxiety by alpha-MSH reactive autoantibodies. Psychoneuroendocrinology 2009;34:140-149.
27.
Spichty R, Balimann M, Barman J, Minder EI: A bioassay for detection of neutralizing antibodies against the alpha-melanocyte stimulating hormone analogue afamelanotide in patients with erythropoietic protoporphyria. J Pharm Biomed Anal 2012;75:192-198.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.